TrialScientific reports2023

A Phase 1 randomized study on the safety and pharmacokinetics of OCS-05, a neuroprotective disease modifying treatment for Acute Optic Neuritis and Multiple Sclerosis.

Pablo Villoslada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.